GlassScriptPhysician profile
Timothy J Mullally
NPI 1366462046
$12,068.53
in general payments reported to CMS, 2019-2025
64 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 94% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $1,234 · 2021: $1,886 · 2022: $1,586 · 2023: $1,953 · 2024: $2,101 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,959 · Education: $77.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,958.89 |
| Education | $77.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,045.31 | 2021-2025 | |
| Novo Nordisk INC | $1,361.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,310.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $710.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $663.02 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $519.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $460.16 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $403.89 | 2022-2025 | Rexulti |
| Allergan, INC. | $297.43 | 2019-2022 | |
| Esperion Therapeutics, INC. | $278.00 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $265.02 | 2019-2022 | |
| Astellas Pharma US INC | $264.34 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $263.34 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $235.11 | 2019-2023 | Xarelto |
| Ironwood Pharmaceuticals, INC | $211.21 | 2020-2024 | Linzess |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mullally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.